Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | HTR2B | P41595 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4959837 | 1.00 | AQP1 (0.47) | AQP1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL4964730 | 1.00 | AQP1 (0.47) | AQP1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL4960551 | 0.86 | AQP1 (0.43) | AQP1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL4964637 | 0.86 | AQP1 (0.47) | AQP1MAPK14 | |
| SCHEMBL4960191 | 0.83 | AQP1 (0.39) | AQP1HTR2AHTR2CHTR2BMAPK14 | |
| SCHEMBL8220563 | 0.82 | CA2 (0.34) | AQP1HTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL4967249 | 0.81 | AQP1 (0.59) | AQP1HTR2AHTR2CHTR2B | |
| SCHEMBL4965170 | 0.81 | AQP1 (0.47) | AQP1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL5361397 | 0.81 | AQP1 (0.51) | AQP1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL5361392 | 0.81 | AQP1 (0.51) | AQP1HTR2AHTR2CHTR2BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | AQP1 1697/4885HTR2A 7/4885HTR2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.